# Deep Research Report: deep-research-pro-preview-12-2025
**Status:** ✅ Success | **Attempts:** 1/5 | **Run ID:** d10e10b4 | **Time:** 837.35s | **Cost:** $4.54158
--------------------------------------------------------------------------------

# The Role of Lagrange Multipliers of Ethical Parameters in Defining the Convergence Domain of Evolutionary Trajectories in Gene Intervention Optimization

### Key Points
*   **Mathematical Translation of Ethics:** In the optimization of gene interventions (such as gene drives), "ethical parameters" are modeled as mathematical **constraints** (e.g., limits on release numbers, spatial confinement, or off-target effects). **Lagrange multipliers** (or adjoint variables in optimal control) associated with these constraints quantify the **shadow price** or marginal cost of adhering to these ethical boundaries in terms of intervention efficacy.
*   **Defining Convergence Domains:** The convergence domain represents the set of initial conditions (e.g., release sizes, allele frequencies) that lead to a successful evolutionary outcome (e.g., vector suppression or population replacement). Ethical constraints, mediated by Lagrange multipliers, reshape this domain; high shadow prices indicate that ethical restrictions are significantly narrowing the window of biological success, potentially rendering the intervention infeasible without relaxing safety standards.
*   **Adjoint Variables as Sensitivity Metrics:** In dynamic modeling software like **GeneDrive.jl**, the optimization process relies on mathematical programming where adjoint variables function as Lagrange multipliers. These variables measure the sensitivity of the objective function (e.g., minimizing disease burden) to changes in state constraints, effectively calculating the "cost" of safety and containment protocols.
*   **Trade-offs in Evolutionary Trajectories:** Optimization algorithms seek the most efficient evolutionary trajectory to fix a desired gene in a population. Lagrange multipliers help identify optimal trade-offs: they reveal exactly how much biological "performance" (speed of fixation, suppression level) must be sacrificed to satisfy ethical constraints (minimizing environmental release, preventing spillover).

### Introduction

The intersection of mathematical biology, optimization theory, and bioethics has emerged as a critical frontier in the deployment of genetic interventions, particularly gene drives intended for vector control. The query regarding the role of **Lagrange multipliers** of **ethical parameters** in defining the **convergence domain** of **evolutionary trajectories** addresses the core mathematical mechanism by which normative values (ethics) are integrated into positive biological models (evolutionary dynamics).

In the context of gene intervention optimization, evolutionary trajectories describe the temporal changes in allele frequencies within a population, governed by forces such as selection, drive efficiency, and migration. The "convergence domain" (or basin of attraction) refers to the specific set of initial conditions and parameters that ensure the system evolves toward a desired stable state, such as the fixation of a therapeutic gene or the suppression of a pest population.

"Ethical parameters" are not intrinsic biological constants but are imposed as **constraints** on the system—for example, limiting the number of transgenic organisms released to minimize ecological disruption, or requiring reversibility. In constrained optimization problems, **Lagrange multipliers** are the mathematical variables introduced to enforce these constraints. Crucially, the value of a Lagrange multiplier at the optimal solution represents the **shadow price** of the constraint: it quantifies the marginal improvement in the objective function (e.g., disease reduction) that could be achieved if the ethical constraint were relaxed by one unit.

Therefore, Lagrange multipliers play a dual role: they enforce ethical boundaries during the calculation of optimal release strategies, and they provide a quantitative metric of the "cost" of ethics. If the Lagrange multipliers associated with ethical constraints are too high, it indicates that the ethical parameters are severely restricting the convergence domain, potentially making the desired evolutionary trajectory unstable or impossible to achieve. This report explores these dynamics through the lens of optimal control theory, mathematical programming (specifically the **GeneDrive.jl** framework), and the economic interpretation of biological constraints.

---

## 1. Theoretical Foundations of Constrained Optimization in Biology

To understand the specific role of Lagrange multipliers in gene intervention, one must first establish the mathematical framework used to model these complex biological systems. The optimization of gene drives is fundamentally a **constrained optimization problem** where an agent (e.g., a public health planner) seeks to maximize a biological outcome subject to physical, biological, and ethical limitations.

### 1.1 The Optimization Problem Structure
In general terms, the optimization of a gene intervention can be formulated as follows:

\[ \text{Minimize } J(u, x) \]
\[ \text{Subject to: } \dot{x} = f(x, u, t) \quad (\text{Evolutionary Dynamics}) \]
\[ g(x, u) \le 0 \quad (\text{Ethical and Operational Constraints}) \]

Where:
*   **\( J \)** is the objective function (e.g., cost of release plus the burden of disease).
*   **\( x \)** represents the state variables (e.g., genotype frequencies, population size).
*   **\( u \)** represents the control variables (e.g., number and timing of modified mosquitoes released).
*   **\( f \)** describes the biological laws (e.g., Mendelian inheritance, gene drive mechanics, population ecology).
*   **\( g \)** represents constraints derived from ethical parameters (e.g., \( u \le U_{max} \) to limit environmental input, or \( x_{wild} \ge X_{min} \) in non-target zones).

### 1.2 Lagrange Multipliers and the Lagrangian Function
The method of Lagrange multipliers allows for the solution of this problem by converting the constrained problem into an unconstrained one. The **Lagrangian** \( \mathcal{L} \) is defined as:

\[ \mathcal{L}(x, u, \lambda, \mu) = J(x, u) + \lambda^T (f(x, u) - \dot{x}) + \mu^T g(x, u) \]

Here, **\( \lambda \)** and **\( \mu \)** are the vectors of Lagrange multipliers.
*   **\( \lambda \)** (often called the **adjoint variable** or **costate** in control theory) is associated with the system dynamics (the evolutionary trajectory).
*   **\( \mu \)** is associated with the inequality constraints (the ethical parameters).

The **Karush-Kuhn-Tucker (KKT)** conditions provide the necessary conditions for optimality. A critical interpretation of the multiplier \( \mu_i \) associated with an ethical constraint \( g_i(x, u) \le 0 \) is that if the constraint is **binding** (i.e., \( g_i = 0 \) at the optimum), then \( \mu_i > 0 \). If the constraint is not binding (the system is well within ethical limits), then \( \mu_i = 0 \).

### 1.3 Shadow Prices and Ethical Costs
The magnitude of the Lagrange multiplier \( \mu_i \) is the **shadow price**. It answers the question: *How much better could the intervention be (in terms of cost or efficacy) if we were allowed to violate this ethical constraint by a small amount?*

In the context of gene drives:
*   If the "ethical parameter" is a limit on the number of released organisms (to prevent public panic or ecological overwhelm), a high Lagrange multiplier indicates that this limit is the primary bottleneck preventing a more effective suppression of the disease vector [cite: 1, 2].
*   Mathematically, the Lagrange multiplier acts as a "force" that pushes the evolutionary trajectory away from the unconstrained optimum and forces it to ride along the boundary of the "ethical domain" [cite: 2, 3].

---

## 2. Evolutionary Trajectories and Convergence Domains

The "evolutionary trajectory" refers to the path a population takes through the space of possible genetic compositions over time. The "convergence domain" is the set of all starting states that eventually lead to the target state under the influence of the intervention.

### 2.1 Dynamics of Gene Drives
Gene drives (e.g., CRISPR/Cas9-based homing drives) alter evolutionary trajectories by biasing inheritance. Instead of the standard 50% transmission rate, a drive allele may be transmitted to 90-100% of offspring.
*   **Unconstrained Trajectory:** Without constraints, a highly efficient drive introduced into a population will spread rapidly, following a logistic-like curve until it reaches fixation (100% frequency) or crashes the population (in suppression drives).
*   **Constrained Trajectory:** When ethical parameters (e.g., "release no more than 1000 insects per week") are applied, the control variable \( u(t) \) is bounded. The trajectory is no longer the fastest possible path to fixation; it becomes a slower, controlled path that must navigate the "allowable" state space defined by the constraints [cite: 4, 5].

### 2.2 The Convergence Domain (Basin of Attraction)
Many gene drives, particularly those designed to be spatially confined or reversible (like underdominance drives), have a **release threshold**. The drive allele must exceed a certain frequency (e.g., 50%) to spread; otherwise, it is purged by natural selection.
*   The **Convergence Domain** is the region of state space above this threshold.
*   **Role of Lagrange Multipliers:** When optimizing a release strategy to push a population into this convergence domain, the Lagrange multipliers associated with resource or ethical constraints determine *feasibility*.
*   If the ethical constraint (e.g., maximum release size) is too strict, the "force" required to push the trajectory across the threshold cannot be generated. The optimization will fail to find a solution, or the Lagrange multiplier will diverge to infinity, signaling that the convergence domain is inaccessible under the current ethical parameters [cite: 6, 7].

### 2.3 Adjoint Variables as Sensitivity Metrics
In dynamic models, the **adjoint variables** (time-dependent Lagrange multipliers) track the sensitivity of the final outcome to the state of the system at any given time \( t \).
*   **Interpretation:** The adjoint variable \( \lambda(t) \) tells us the "value" of adding one more drive-carrying individual to the population at time \( t \).
*   **Ethical Link:** If an ethical constraint prevents releasing individuals at time \( t \), the adjoint variable quantifies the "opportunity cost" of that missed opportunity. This helps quantify the trade-off between "acting ethically" (minimizing intervention) and "acting effectively" (ensuring convergence) [cite: 4, 5].

---

## 3. GeneDrive.jl: A Case Study in Optimization and Adjoints

The most explicit application of these concepts is found in the software framework **GeneDrive.jl**, developed to optimize vector control strategies. This tool represents a shift from classical continuous optimal control to **discretized mathematical programming**, but the role of Lagrange multipliers remains central.

### 3.1 From Hamiltonians to Mathematical Programming
Classically, biological optimization uses the **Pontryagin Maximum Principle**, which involves maximizing a **Hamiltonian** function. The Hamiltonian is effectively an instantaneous Lagrange expression [cite: 4].
*   **The Hamiltonian:** \( H = L + \lambda^T f \), where \( \lambda \) are the adjoints (Lagrange multipliers).
*   **GeneDrive.jl Approach:** This software discretizes the system into a nonlinear programming (NLP) problem. In this formulation, the constraints (both biological dynamics and operational/ethical limits) are handled directly. The solver computes Lagrange multipliers for every constraint to check for optimality (KKT conditions) [cite: 5, 8].

### 3.2 Adjoints as Marginal Costs of Constraints
Research explicitly states that in these formulations, "the adjoints can be interpreted as Lagrange multipliers associated with the state equations which constitute the marginal cost of violating those constraints" [cite: 4, 9].
*   **Application:** When GeneDrive.jl optimizes a release schedule to suppress mosquitoes while adhering to a budget or a "maximum release" constraint (an ethical proxy for environmental impact), the software calculates the optimal path.
*   **Feedback Loop:** If the user sets an ethical parameter (e.g., "Do not release during sensitive season X"), the solver introduces a constraint. The associated Lagrange multiplier reveals the "cost" of this ethical decision. If the multiplier is zero, the ethical constraint is not hindering efficacy. If it is high, the constraint is actively preventing the system from reaching a better evolutionary outcome [cite: 5, 10].

### 3.3 Stochasticity and Robustness
GeneDrive.jl also incorporates stochasticity (e.g., weather variability). In stochastic optimization, Lagrange multipliers become random variables or distributions. They help define a **robust convergence domain**—a set of strategies that work *despite* uncertainty, provided the ethical constraints are not violated. The "price" of robustness often appears as higher expected costs or larger required releases, reflected in the shadow prices [cite: 9, 11].

---

## 4. Ethical Parameters as Mathematical Constraints

To fully answer the query, we must detail *how* ethical parameters are parameterized and how Lagrange multipliers interact with them.

### 4.1 Types of Ethical Constraints
1.  **Biosafety/Containment:** Limiting the spread of the gene drive to a target region.
    *   *Math:* Inequality constraint on allele frequency in neighboring patches: \( x_{neighbor} \le \epsilon \).
    *   *Lagrange Multiplier:* Represents the "pressure" the drive exerts to escape. A high multiplier means the drive is highly invasive, and containing it requires significant "force" (or suboptimal efficacy in the target zone).
2.  **Intergenerational Equity:** Avoiding irreversible changes or ensuring the drive can be removed.
    *   *Math:* Constraint on the availability of a "reversal" drive or a limit on the drive's persistence time.
    *   *Lagrange Multiplier:* The cost in terms of reduced suppression duration required to ensure reversibility.
3.  **Animal Welfare:** Minimizing the total number of organisms involved or suffering.
    *   *Math:* Minimizing \( \int u(t) dt \) or constraining the peak population size.
    *   *Lagrange Multiplier:* The loss of control efficacy per unit of animal welfare preserved.

### 4.2 The "Shadow Price" of Ethics
The concept of **shadow price** is pivotal. In economics, the shadow price is the value of a resource. In gene intervention, the "resource" is the *freedom to intervene*. Ethical parameters restrict this freedom.
*   **Source 33** and **Source 35** discuss estimating the shadow price of societal opportunity costs in healthcare. Similarly, in gene drives, if an ethical constraint (e.g., "obtain community consent before increasing release size") delays action, the Lagrange multiplier associated with the time-constraint quantifies the health burden (e.g., malaria cases) accrued during that delay [cite: 1, 12].
*   **Source 53** applies shadow prices to metabolic flux, showing how constraints force the system into suboptimal states. Analogously, ethical constraints force the evolutionary trajectory of a gene drive into a "suboptimal" path (biologically speaking), slowing down fixation or suppression to maintain ethical standards [cite: 13].

---

## 5. Defining the Convergence Domain

The convergence domain is not static; it is shaped by the constraints.

### 5.1 Shrinking the Domain
Lagrange multipliers help map the boundaries of the **feasible convergence domain**.
*   Imagine a landscape where "altitude" is the cost function. The system tries to roll downhill to the "success" state.
*   Ethical constraints act as walls or fences.
*   The Lagrange multiplier measures the force the system exerts against these walls.
*   If the ethical parameters are too strict (e.g., "zero off-target mutations allowed"), the feasible region may shrink to the point where it contains *no* evolutionary trajectories that lead to the target (e.g., disease eradication). The convergence domain becomes empty [cite: 6, 7].

### 5.2 Identifying "Living on the Edge"
Source 65 discusses "Safe Minimum Standards" and "Living on the Edge of Risk" using shadow prices. In gene drives, optimal strategies often lie on the boundary of the ethical constraints (e.g., releasing *exactly* the maximum allowable number of mosquitoes).
*   The Lagrange multiplier tells us how precarious this position is. A very high multiplier suggests that a slight tightening of ethical standards would cause the strategy to fail (the trajectory would fall out of the convergence domain) [cite: 14].

---

## 6. Comparative Analysis: Clinical and Economic Optimization

The use of Lagrange multipliers to balance efficiency with ethical constraints is not unique to gene drives; parallels in clinical trials and economics reinforce the concept.

### 6.1 Clinical Trials (CARA)
Sources 26 and 28 discuss **Covariate-Adjusted Response-Adaptive (CARA)** randomization.
*   **Goal:** Estimate treatment effects efficiently (scientific goal).
*   **Ethical Constraint:** Treat as many patients as possible with the *better* drug during the trial.
*   **Mechanism:** The optimization problem uses Lagrange multipliers to handle the constraints on allocation probabilities. The multipliers balance the "information gain" (variance reduction) against the "ethical cost" (treating patients with inferior drugs) [cite: 15, 16].
*   **Relevance:** This mirrors gene drive optimization, where the goal is scientific/public health success, constrained by the ethics of deployment.

### 6.2 Economic Emission Dispatch
Source 50 describes using Lagrange multipliers for **economic emission dispatch**—balancing power generation cost with environmental (ethical) emission constraints.
*   The Lagrange multiplier converts the multi-objective problem (Cost vs. Pollution) into a single objective by pricing the pollution.
*   Similarly, in gene drives, Lagrange multipliers "price" the ethical violations (e.g., environmental risk), allowing the algorithm to find a trajectory that minimizes the weighted sum of economic cost, disease burden, and ethical risk [cite: 17].

---

## 7. Conclusion

In the optimization of gene interventions, **Lagrange multipliers** are not merely abstract coefficients; they are the quantitative bridge between **normative ethics** and **positive evolutionary biology**.

1.  **Defining Feasibility:** They determine whether a successful evolutionary trajectory exists within the "ethical boundaries" set by society. If the multipliers associated with ethical constraints diverge, the convergence domain is empty—the intervention cannot succeed without compromising ethics.
2.  **Quantifying Trade-offs:** They provide the **shadow price** of ethical parameters. They tell decision-makers exactly how much biological efficacy (e.g., speed of vector suppression) is being "paid" to maintain a specific safety standard or containment protocol.
3.  **Guiding Optimization:** In software like **GeneDrive.jl**, adjoint variables (dynamic Lagrange multipliers) guide the search for optimal release schedules. They identify the "path of least resistance" that navigates the complex landscape of population genetics while bouncing off the "walls" of ethical constraints.

Ultimately, Lagrange multipliers allow us to rigorously define the **convergence domain** not just as a biological reality, but as a **bio-ethical reality**. They reveal that the set of successful evolutionary trajectories is determined as much by our values (constraints) as by the genes themselves.

### References
*   **[cite: 6, 7]** Control design and convergence domains in networked evolutionary games.
*   **[cite: 15, 16]** Efficiency bounds and ethical constraints in clinical trials (CARA) using Lagrange multipliers.
*   **[cite: 1, 12]** Shadow prices and societal opportunity costs in healthcare resource allocation.
*   **[cite: 5]** GeneDrive.jl: A simulation framework for gene drive systems.
*   **[cite: 3]** Lagrange multipliers as "fail-safe" tools in optimization.
*   **[cite: 17]** Lagrange multipliers in economic emission dispatch (balancing cost and environment).
*   **[cite: 13]** Shadow prices in metabolic flux analysis (biological constraints).
*   **[cite: 2]** Optimality in biology and the role of adjoint variables as shadow prices.
*   **[cite: 14]** Safe Minimum Standards and shadow prices in dynamic resource problems.
*   **[cite: 4]** Mathematical programming for gene drive optimization; adjoints as Lagrange multipliers/marginal costs.
*   **[cite: 9]** Stochastic optimization in GeneDrive.jl and robust intervention planning.
*   **[cite: 5, 8]** GeneDrive.jl software architecture and the use of constrained optimization.
*   **[cite: 18]** Pontryagin's maximum principle and Lagrange multipliers in adaptive dynamics.
*   **[cite: 10]** Review of gene drive modeling and risk assessment implications.

## Detailed Report

### 1. Introduction: The Bio-Mathematical Interface of Ethics

The deployment of gene interventions—specifically gene drives designed to suppress or replace populations of disease vectors—presents a complex optimization problem. This problem is not solely biological; it is deeply constrained by ethical parameters. These parameters, which may include mandates for spatial containment, reversibility, minimization of release numbers, or protection of non-target species, act as boundaries within which the biological system must operate.

The query asks for the role of **Lagrange multipliers** of these ethical parameters in defining the **convergence domain** of **evolutionary trajectories**. This requires bridging two distinct fields: **optimal control theory** (where Lagrange multipliers, often called adjoints or costates, reside) and **population genetics** (which describes evolutionary trajectories).

In this context, Lagrange multipliers serve as the mathematical "currency" that translates ethical constraints into biological trade-offs. They define the **convergence domain**—the set of initial conditions capable of reaching a successful outcome—by quantifying the "cost" of adhering to ethical limits. If the shadow price (Lagrange multiplier) of an ethical constraint is too high, it implies that the constraint is actively preventing the system from converging to the desired biological state (e.g., disease eradication).

### 2. Mathematical Framework of Gene Intervention Optimization

To understand the role of Lagrange multipliers, we must first define the optimization problem inherent in gene drive deployment.

#### 2.1 The Dynamic System (Evolutionary Trajectories)
The evolution of a gene drive is typically modeled using systems of ordinary differential equations (ODEs) or difference equations. These equations describe the change in allele frequencies over time.
*   Let \( x(t) \) be the state vector representing the frequency of the drive allele and the wild-type allele in a population at time \( t \).
*   Let \( u(t) \) be the control input, representing the release of genetically modified organisms (GMOs) into the population.

The **evolutionary trajectory** is the path \( x(t) \) takes through the state space from an initial condition \( x(0) \) to a final state \( x(T) \). The dynamics are governed by:
\[ \dot{x}(t) = f(x(t), u(t), t) \]
where \( f \) encapsulates the biological rules of inheritance (e.g., homing efficiency, fitness costs) and ecology (e.g., mating, death rates) [cite: 4, 5].

#### 2.2 Ethical Parameters as Constraints
Ethical considerations are not usually variables in the equations of motion; rather, they are **constraints** on the system.
*   **Safety/Containment:** "The frequency of the drive allele in a non-target neighboring population must not exceed 1%." Mathematically: \( x_{neighbor}(t) \le 0.01 \).
*   **Resource/Welfare:** "The total number of released mosquitoes must not exceed \( N_{max} \)." Mathematically: \( \int_{0}^{T} u(t) dt \le N_{max} \).
*   **Temporal Constraints:** "The intervention must achieve suppression within 2 years." Mathematically: \( x_{target}(T) \le \text{Threshold} \) where \( T = 2 \text{ years} \).

#### 2.3 The Optimization Problem
The goal is to minimize a cost function \( J \) (e.g., the burden of malaria plus the cost of rearing mosquitoes) subject to these constraints.
\[ \text{Minimize } J = \int_{0}^{T} L(x, u, t) dt + \Phi(x(T)) \]
Subject to:
\[ \dot{x} - f(x, u, t) = 0 \]
\[ g(x, u, t) \le 0 \quad (\text{Ethical Constraints}) \]

### 3. The Role of Lagrange Multipliers (Adjoints)

In constrained optimization, we form the **Lagrangian** function by appending the constraints to the objective function using weighted multipliers.

#### 3.1 Adjoint Variables in Optimal Control
In the context of dynamic systems (like gene drives), the Lagrange multipliers associated with the system dynamics \( \dot{x} = f(x, u) \) are called **adjoint variables** or **costates**, denoted by \( \lambda(t) \).
*   **Source 74** and **Source 85** explicitly state: "The states in these formulations represent constraints of the minimization... and the adjoints can be interpreted as Lagrange multipliers associated with the state equations which constitute the marginal cost of violating those constraints."
*   The adjoint variable \( \lambda(t) \) evolves backward in time and tells the optimizer how sensitive the final objective \( J \) is to changes in the state \( x \) at time \( t \).

#### 3.2 Multipliers for Ethical Constraints
For the explicit ethical constraints \( g(x, u) \le 0 \), we introduce a separate set of Lagrange multipliers, often denoted as \( \mu(t) \).
*   **The Shadow Price Interpretation:** The value of \( \mu(t) \) represents the **shadow price** of the ethical constraint. It quantifies the rate of change of the optimal objective value with respect to the constraint limit.
*   **Example:** If \( g(x, u) \) limits the release size to 1000 insects, and the associated multiplier \( \mu \) is high, it means that allowing 1001 insects would significantly improve the outcome (e.g., drastically reduce the time to suppression). The high multiplier signals that the ethical constraint is the primary limiting factor of the intervention's success [cite: 1, 2].

### 4. Defining the Convergence Domain

The **convergence domain** (or basin of attraction) is the set of all initial conditions \( x(0) \) and control strategies \( u(t) \) that allow the system to reach the desired stable equilibrium (e.g., pathogen elimination).

#### 4.1 How Constraints Reshape the Domain
Unconstrained, a gene drive might have a large convergence domain—simply releasing a handful of organisms might be enough to trigger a self-sustaining spread (fixation). However, ethical parameters (constraints) reshape this landscape.
*   **Constricting the Basin:** If an ethical parameter dictates that releases must be "small and gradual" (to monitor for side effects), the "push" provided by the control \( u(t) \) is weak. This might make it impossible to overcome the Allee effect or the fitness cost of the drive. The convergence domain shrinks; only starting populations with specific characteristics (e.g., low density) might be successfully treated.
*   **Lagrange Multipliers as Boundary Indicators:** The Lagrange multipliers define the boundaries of this feasible domain. When the optimization solver attempts to find a solution, if the trajectory hits the "wall" of an ethical constraint (e.g., maximum release limit reached), the multiplier becomes positive. If the multiplier tends toward infinity, it indicates that the constraint is incompatible with convergence—the domain has effectively vanished [cite: 6, 7].

#### 4.2 "Living on the Edge" of Risk
**Source 65** discusses "Safe Minimum Standards" and the concept of "living on the edge of risk." In gene drive optimization, the optimal trajectory often rides exactly along the boundary of the ethical constraints.
*   For example, to maximize suppression while minimizing release (an ethical/economic goal), the optimal strategy might be to release *exactly* the maximum amount allowed by the safety protocol, but no less.
*   The Lagrange multiplier at this boundary measures the "tension." A high tension implies that the system is barely staying within the convergence domain; any stochastic fluctuation (e.g., bad weather, unexpected migration) could push the system into failure [cite: 9, 14].

### 5. Case Study: GeneDrive.jl and Computational Implementation

The theoretical role of Lagrange multipliers is operationalized in software packages like **GeneDrive.jl**.

#### 5.1 Mathematical Programming vs. Optimal Control
While classical biology uses continuous optimal control (Pontryagin's Principle), **GeneDrive.jl** uses **mathematical programming** (discretized optimization).
*   **Source 84** and **Source 110** explain that GeneDrive.jl formulates the problem as a constrained nonlinear program (NLP).
*   In this NLP, the "ethical parameters" (e.g., spatial restrictions, budget limits) are explicit inequality constraints.
*   The solver (e.g., IPOPT or SNOPT) computes the Lagrange multipliers for these constraints numerically. These multipliers are used to check the **Karush-Kuhn-Tucker (KKT)** conditions, ensuring that the solution is indeed optimal.

#### 5.2 Practical Utility of the Multipliers
For a researcher using GeneDrive.jl:
*   The Lagrange multipliers provide feedback on the **design of the intervention**.
*   If the multiplier for "Spatial Containment" is extremely high, it tells the researcher: "Your desire to keep the drive contained is making it incredibly expensive or difficult to suppress the vector in the target zone."
*   This allows for an informed ethical debate: Is the safety margin too high? Should we relax the constraint to achieve the public health goal? The Lagrange multiplier quantifies the "cost of ethics" in terms of human health [cite: 10, 19].

### 6. Parallels in Other Fields

The use of Lagrange multipliers to manage ethical constraints is not unique to gene drives.

*   **Clinical Trials (CARA):** **Source 26** and **Source 28** describe optimizing clinical trial designs using Lagrange multipliers. The "ethical parameter" is the requirement to treat patients effectively during the trial (not just learn about the drug). The multipliers balance the "learning" objective against the "healing" constraint. This mirrors the gene drive trade-off between "learning/suppressing" and "safety/containment."
*   **Economic Emission Dispatch:** **Source 50** uses Lagrange multipliers to balance power generation (utility) with emission limits (environmental ethics). The multiplier acts as a "carbon tax" or shadow price, internalizing the ethical constraint into the economic model.

### 7. Conclusion

In the optimization of gene interventions, **Lagrange multipliers** play a foundational role in defining the **convergence domain** of **evolutionary trajectories**. They act as the mathematical enforcement mechanism for **ethical parameters**, translating qualitative values (safety, containment, welfare) into quantitative constraints.

By measuring the **shadow price** of these constraints, Lagrange multipliers reveal the topology of the feasible solution space. They indicate when ethical parameters are shrinking the convergence domain to the point of infeasibility, and they quantify the trade-offs between ethical compliance and biological efficacy. In computational tools like **GeneDrive.jl**, these multipliers are the engine that guides the discovery of strategies that are both evolutionarily successful and ethically sound.

### References
*   **[cite: 6, 7]** *Control design to minimize the number of bankrupt players for networked evolutionary games...* (Discusses convergence domains and control invariant subsets).
*   **[cite: 15, 16]** *On the achievability of efficiency bounds for covariate-adjusted response-adaptive randomization* (Discusses Lagrange multipliers and ethical constraints in clinical trials).
*   **[cite: 1, 12]** *Incorporating Resource Constraints in Health Economic Evaluations* (Discusses shadow prices and societal opportunity costs).
*   **[cite: 5, 8]** *GeneDrive.jl: A decision tool to optimize biological vector control strategies...* (Primary source on gene drive optimization, mathematical programming, and adjoints/Lagrange multipliers).
*   **[cite: 3]** *Lagrange Multipliers* (General theory on "fail-safe" optimization).
*   **[cite: 17]** *Economic Emission Dispatch using Lagrange Multiplier...* (Parallel application in environmental ethics).
*   **[cite: 13]** *Shadow Prices of Metabolic Flux...* (Biological application of shadow prices).
*   **[cite: 2]** *Optimality and dynamics: optimal control theory* (Discusses adjoint variables as shadow prices in biology).
*   **[cite: 14]** *Safe Minimum Standards in Dynamic Resource Problems...* (Discusses shadow prices and risk thresholds).
*   **[cite: 4]** *Applications of Mathematical Programming to Genetic Biocontrol* (Explicitly links adjoints to Lagrange multipliers and marginal costs of constraints).
*   **[cite: 9]** *Stochastic Programming Optimization...* (Discusses robust optimization in GeneDrive.jl).
*   **[cite: 18]** *The canonical equation of adaptive dynamics...* (Discusses Pontryagin's maximum principle and Lagrange multipliers in evolutionary dynamics).
*   **[cite: 10]** *Review of gene drive modelling and implications for risk assessment...* (Contextualizes GeneDrive.jl and optimization).

**Sources:**
1. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa8Bv-qGqRsBsoZDSQ83OiQtFw3LHaq_EO39QpuZ7DXGWpUE2QLMykWc18G2FQWQX1jbyAbt0lA2pByLmfKxaxibys8hYUnmvIRMDbFupzzqqd9u7YiZGWIJfTYPs6dkxs36R661tcxQ==)
2. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFca7ATJGqD5GtawXGbrzcZcJoLBqFPQjXFoPyhMLuPrBBrwgNeT807zryeG-j1TN62j8NQGLc3e47xZWXP2ZFDWetBErNVZ7EqWEi8Pu1rq3yCvvOHgBT3cPuX5yVsiox_krzNxyDa)
3. [informs.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBYATaLTn7sBYi8NpTG6OD9Aznq1oXhG72fuiMMgVMeMBgRVkrhV-eFeJPpo57ERpu71p8kjLrMqPd8VHtaR2fHMb6KUaU6vgy2kDbtt42ZknQyWWTQ0D1NgID086NMPaV_j-KQy_dRqLpKj8vWA==)
4. [escholarship.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFv-JxPtj3v-QwmMn-j87mhIfFljjWqbiGJKiHlEMk5zw2NOukyKHT28zt6UwDWDY3ZGf0MQPVW-T0Po25qiayNsDn70n1uBecPxO0HJTN6CzqoNTDNqzjenYigC_9zQK59FsqK64zNiNRuCxSJm7lG)
5. [berkeley.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-oZHp4pPMsmernyW03DSszhLsfL5XmTsRc_uUrA_KWnltmAiIBA7BLsif6hSzeniEbkw9mhC4Db2jUYPQOm8G8CKv-ycsrUM-sdPCttDMiISw8QFkRzRnhPwLloOuSpuooKZJbOSFvS6MlDKZS5cPonHm7cWT31A=)
6. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeyKTYv8vfY4noCGWVtnUmUX8hbf24y6LPUCLcLWzzSIC2ieRzJRjIcPwo1-Z6_qvIvc-PIvYZDoMXeyHBsM1IOmcLlle8lAdWRHOp78xd1HaIzqSq4IdkXMJ9Vw_WQHmpWFrtp8ZiI3mNCYwB0ZIszkImBP82q57CK39y4uIMex8sxgB6i4f2MpbnXc0Y-wwlaOqS6TtFeyUoXeiOF8n1VGf0Gw0yPVeHFBJMmvj0bBpqSM1csZVvPKt_jkhX1otJZINjRwqTKWCrGbH83dBI1e4upumaOMp_q5GSZ1Y=)
7. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFFnrOoBRAP363aXKYOFE3kAlhDkDUTOau-EwzgkMUQFRvBcD3KcFsZxQD0zrCHu2kSjRPt833IDUGNNINM9kWV8NZGmeCqwUehwm6bJs035Uu2Z0Af_j57L8b0S8MC2CftfZgnVUwjvZlE4GYOgtc0UQNx16DMO8I6ep7QR4brA2-mKw_aHGrAu_yZ54vFeWLjXkd8P_uAX-kuubdt6MKkv8GWZm7d_zi5dfyJPXktLhnrbeFXxxX-rL17ADIeXKJFkae2RGqaDbpvKRR6hNFsrwKIQgcJVLYRErUeyJRmu5PUNIZMbltqC8zaV_dEy0ky2R6BOSFgRrbjr67yVGLwHaO88WTlHIYz-sf5d32-_4y0UgiA02sCwRAo2RwxMxNd9R3xGEKlCuMFjS26GIBrh9SHpCoVYWbwwtw2jKEkx2PvtSGzi75FEi03EkOamfKBptP04hJBKZ20MpsCXjqLeJRldvh6E9-faMHNIGU-H5q6UcHd47ZBA==)
8. [plos.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFh53XqERnWZqPkRiThDwR9sYy5K_9fh2RzSILLBgnbI7weUcHnj9kaCtB6Q_nkftZO5ZmmZ5krC02RLLyuf4LCRnkhZ7Ey7z_Q4oc-jHRTY_AJNzAzLC7LWJK4krIbdQCADSGAcPWGdYOiSObem2hiV3YeJxrdmJDhlmT7EZt5OWivX6g=)
9. [escholarship.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFl9EDBoadPPswC29Fp7bXtTj2chlUX-18XZgXhTyPk5lDdrRmWT4Ou65duH2KtAExMznpX-VuGnRbPnjRA2CuUfDQlWTq0efG9k2Q4v2FIQQPKdL2YhCyT81FI4zZY01He2g1YIEa0tyu4-H7S6Gb)
10. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzDTVXrXgSBCCjwzxsBEP-MDf8xcF5GhPgJmXckPK_yGQjfHhIRuXTktzapXE6a9LoTs0KFJs3KDIIcjw5eGoRzxKJcItxd_70Ad8Ex0uCYyj1j34QfAemogNPdUcs4OY_ME2AVYoz6hVqMSuw6Q7e7tCZ_onWcC5mr1It08_JOnjXI-6qmffl1fTdcKFX48qckF_85YQBYDd6Bw53gf2jbihuh87pAoDcFrJjfQ7w8t9ejWVcFzRcFI9xNTsXSwScZ0Y1wA==)
11. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHtoNRiF95wCg8st5Hfv49NI1oCYeOkSCTnivZwx6CnRlXM6ED5EXirZDWQtc6LYBujG0nhtEqA9qzdaItkmT_AuwpPcAee1rREl-i587dHvqYG6fmQ_-kpFmgrbmBVQWtqS7fi9NBEXFbB6zdFRzczABLjRwiufzkTOgk1uxQZ3bszaMOyvgBdcTWio2EDm5PYxzDSEabglljqi2D_0neO62qps_A=)
12. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGR4VbYxtue6YbMuKei4mPcnjDTf-saHdXjKoLXYaO8Ee4eQ58WiXqF4AstFBoIZ_4lqBrGWzhdKa4v_xwr1hGTB40OTI6oxl0wzlWj91oxRbVST7iHZVbBBjR9Fp8iifxj3DwKlXx1ZHLuR0-2qSTFr1tzyYU5Z0JX-IOCBijJIbvivhQzAHgeWHKUDchLAobnG1uYQa7LuA5pboYO9nZiZUC0lj1dVTBJn-lGWTzVjqrY1S5qvg2Oh3Y93Y3jUfsQR35ZQqKdIWtEmgJ1nvTm5La-G8fTk7Z8gZtP7WXQxWY80w==)
13. [plos.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFjQnKkuIGXegkojun8BjLgc55orBZ7Y92HgL1jjnbuF8ZsHdHnZvuHcQ3Cq4DpRlJZQm1CBf1xuuX0fH_7ZOyYRJ8asc521Ci_Jy7wtCRPtSHJZsRHIdAW2g4O8joUDwDs7vmk9DTEepSgotSbkRCs49csrB9KKi-xK2xBlmehjuGFdg0=)
14. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFW-Pxky1wGb504gRv3mMbXSZEM-81X8Z7B_tovP4sb926fE6-xVlYx5tTVbqtEGdn6mdWOHDhSMB3jF3r1YekUIojxo8OgLVhnqoijZRcg2NwCmBJpxk5OyZFfv1NW9T9qLrlxoRBlFst4eXpE7wkFV5H-auZuZt5u-vHcXsXspuh7QuOl0wfHB8b8G6VHhrlXhk_jvc-ac9kETpvpf_PoKrJXiZCWPhqXoPwbn-i9L4V08cqC4_oVtrJHEaY9GIIycEu6CQ==)
15. [arxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8GQNV6EHzQnLT4jfgCEjgfyERwvm_unPbuV_vABJ2MxJ8ZIkKDaG1gFeqWJf37kscef7tXL8mk2vluU9nVq8qUVdV55H-EHRIMPYc-Uz3pTAbFKjOlA==)
16. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFrlsik6w8ReVqkoG4M4QZVCKZFVxX1Kvu68mii1B-wuJs95d59bw_RBjTMWds9zGdMUE9EGsjBgoeYG9okhP589bMBHHOz-mFxFBWhAPAtnnLE--16NH3mkvhpuBEjImVpGM3Q9gUMQO4sJ06OlTCCe_UxlrB9UqWsbIYlRREelCwwu_zXA2zcl9S7MwLrbvhutHDRkdKWVq0BV28AQB4wI7Bbyv5W_MlkysvN5oy8NCPwnAGpusTEGXTTrFf7m4hCIqpaaq85NzN2)
17. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqXRlzDVoWa30-CzmWFwPNfRLmumKlvd5Y4t8ugONjF0F_37KF8rBkLZc_XeXBHbDwAywQDCK1vIddS_D5UNh5GporhG4VXVDrzLGkdTIRALWLGtuUayjMz8ypqWWP)
18. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9RLXHOAkZXR0w_-FOkWM23Qfk-F7cJrGSH5GteasKpFHorTHy4Ns0sBfg6K--rIs33xXvEKao-OHnPbvAxcGPlal7FK0R6rwUCWULLaXdu1EjWoMi-YFaRA2l5AlqoEo62gAHp_AcL0zaJFa0iXHw1NvdZni3oH68wsVDazfFui6O_VNK7mes8GyUq4nz8ajV4BRHM-QAcs2DQLdGNRuQer3mHUnkSgwyfdS4LgtPPfevy-xzdp_q7_aznRtnK632DPhRp7TlHymwItyiescICtJ8S7BYtM95QltFTZcMJJZoXv1Q9T9WxmIoTQnMn1xRQ5QkRXZG)
19. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHlhNEmFC6B4qw2yLSWILFZagATy5TGszpSjqBwdM0sbwljmDgGWZAn9kbmplBaSgm0mUzE-Ox-eY4M4d-u4zQ9VsiWFpGqFZWYIYQvSQvXmMcIn8h89H1OA03EV6P1m-U94oo4lagYtiODFRfWI2Hfc03SozHJ-yF7zJvDH_z5WhxjsUic4l8uIJEZ8_mP6AeGnu23iX9FYxKpQJKnjHw6vuY3N23N5A==)


## Annotations
Annotation(end_index=7467, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa8Bv-qGqRsBsoZDSQ83OiQtFw3LHaq_EO39QpuZ7DXGWpUE2QLMykWc18G2FQWQX1jbyAbt0lA2pByLmfKxaxibys8hYUnmvIRMDbFupzzqqd9u7YiZGWIJfTYPs6dkxs36R661tcxQ==', start_index=7455)
Annotation(end_index=7467, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFca7ATJGqD5GtawXGbrzcZcJoLBqFPQjXFoPyhMLuPrBBrwgNeT807zryeG-j1TN62j8NQGLc3e47xZWXP2ZFDWetBErNVZ7EqWEi8Pu1rq3yCvvOHgBT3cPuX5yVsiox_krzNxyDa', start_index=7455)
Annotation(end_index=7684, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFca7ATJGqD5GtawXGbrzcZcJoLBqFPQjXFoPyhMLuPrBBrwgNeT807zryeG-j1TN62j8NQGLc3e47xZWXP2ZFDWetBErNVZ7EqWEi8Pu1rq3yCvvOHgBT3cPuX5yVsiox_krzNxyDa', start_index=7672)
Annotation(end_index=7684, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBYATaLTn7sBYi8NpTG6OD9Aznq1oXhG72fuiMMgVMeMBgRVkrhV-eFeJPpo57ERpu71p8kjLrMqPd8VHtaR2fHMb6KUaU6vgy2kDbtt42ZknQyWWTQ0D1NgID086NMPaV_j-KQy_dRqLpKj8vWA==', start_index=7672)
Annotation(end_index=8879, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-oZHp4pPMsmernyW03DSszhLsfL5XmTsRc_uUrA_KWnltmAiIBA7BLsif6hSzeniEbkw9mhC4Db2jUYPQOm8G8CKv-ycsrUM-sdPCttDMiISw8QFkRzRnhPwLloOuSpuooKZJbOSFvS6MlDKZS5cPonHm7cWT31A=', start_index=8867)
Annotation(end_index=8879, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFv-JxPtj3v-QwmMn-j87mhIfFljjWqbiGJKiHlEMk5zw2NOukyKHT28zt6UwDWDY3ZGf0MQPVW-T0Po25qiayNsDn70n1uBecPxO0HJTN6CzqoNTDNqzjenYigC_9zQK59FsqK64zNiNRuCxSJm7lG', start_index=8867)
Annotation(end_index=9865, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFFnrOoBRAP363aXKYOFE3kAlhDkDUTOau-EwzgkMUQFRvBcD3KcFsZxQD0zrCHu2kSjRPt833IDUGNNINM9kWV8NZGmeCqwUehwm6bJs035Uu2Z0Af_j57L8b0S8MC2CftfZgnVUwjvZlE4GYOgtc0UQNx16DMO8I6ep7QR4brA2-mKw_aHGrAu_yZ54vFeWLjXkd8P_uAX-kuubdt6MKkv8GWZm7d_zi5dfyJPXktLhnrbeFXxxX-rL17ADIeXKJFkae2RGqaDbpvKRR6hNFsrwKIQgcJVLYRErUeyJRmu5PUNIZMbltqC8zaV_dEy0ky2R6BOSFgRrbjr67yVGLwHaO88WTlHIYz-sf5d32-_4y0UgiA02sCwRAo2RwxMxNd9R3xGEKlCuMFjS26GIBrh9SHpCoVYWbwwtw2jKEkx2PvtSGzi75FEi03EkOamfKBptP04hJBKZ20MpsCXjqLeJRldvh6E9-faMHNIGU-H5q6UcHd47ZBA==', start_index=9853)
Annotation(end_index=9865, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeyKTYv8vfY4noCGWVtnUmUX8hbf24y6LPUCLcLWzzSIC2ieRzJRjIcPwo1-Z6_qvIvc-PIvYZDoMXeyHBsM1IOmcLlle8lAdWRHOp78xd1HaIzqSq4IdkXMJ9Vw_WQHmpWFrtp8ZiI3mNCYwB0ZIszkImBP82q57CK39y4uIMex8sxgB6i4f2MpbnXc0Y-wwlaOqS6TtFeyUoXeiOF8n1VGf0Gw0yPVeHFBJMmvj0bBpqSM1csZVvPKt_jkhX1otJZINjRwqTKWCrGbH83dBI1e4upumaOMp_q5GSZ1Y=', start_index=9853)
Annotation(end_index=10585, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-oZHp4pPMsmernyW03DSszhLsfL5XmTsRc_uUrA_KWnltmAiIBA7BLsif6hSzeniEbkw9mhC4Db2jUYPQOm8G8CKv-ycsrUM-sdPCttDMiISw8QFkRzRnhPwLloOuSpuooKZJbOSFvS6MlDKZS5cPonHm7cWT31A=', start_index=10573)
Annotation(end_index=10585, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFv-JxPtj3v-QwmMn-j87mhIfFljjWqbiGJKiHlEMk5zw2NOukyKHT28zt6UwDWDY3ZGf0MQPVW-T0Po25qiayNsDn70n1uBecPxO0HJTN6CzqoNTDNqzjenYigC_9zQK59FsqK64zNiNRuCxSJm7lG', start_index=10573)
Annotation(end_index=11242, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFv-JxPtj3v-QwmMn-j87mhIfFljjWqbiGJKiHlEMk5zw2NOukyKHT28zt6UwDWDY3ZGf0MQPVW-T0Po25qiayNsDn70n1uBecPxO0HJTN6CzqoNTDNqzjenYigC_9zQK59FsqK64zNiNRuCxSJm7lG', start_index=11233)
Annotation(end_index=11701, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-oZHp4pPMsmernyW03DSszhLsfL5XmTsRc_uUrA_KWnltmAiIBA7BLsif6hSzeniEbkw9mhC4Db2jUYPQOm8G8CKv-ycsrUM-sdPCttDMiISw8QFkRzRnhPwLloOuSpuooKZJbOSFvS6MlDKZS5cPonHm7cWT31A=', start_index=11689)
Annotation(end_index=11701, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFh53XqERnWZqPkRiThDwR9sYy5K_9fh2RzSILLBgnbI7weUcHnj9kaCtB6Q_nkftZO5ZmmZ5krC02RLLyuf4LCRnkhZ7Ey7z_Q4oc-jHRTY_AJNzAzLC7LWJK4krIbdQCADSGAcPWGdYOiSObem2hiV3YeJxrdmJDhlmT7EZt5OWivX6g=', start_index=11689)
Annotation(end_index=11981, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFl9EDBoadPPswC29Fp7bXtTj2chlUX-18XZgXhTyPk5lDdrRmWT4Ou65duH2KtAExMznpX-VuGnRbPnjRA2CuUfDQlWTq0efG9k2Q4v2FIQQPKdL2YhCyT81FI4zZY01He2g1YIEa0tyu4-H7S6Gb', start_index=11969)
Annotation(end_index=11981, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFv-JxPtj3v-QwmMn-j87mhIfFljjWqbiGJKiHlEMk5zw2NOukyKHT28zt6UwDWDY3ZGf0MQPVW-T0Po25qiayNsDn70n1uBecPxO0HJTN6CzqoNTDNqzjenYigC_9zQK59FsqK64zNiNRuCxSJm7lG', start_index=11969)
Annotation(end_index=12649, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-oZHp4pPMsmernyW03DSszhLsfL5XmTsRc_uUrA_KWnltmAiIBA7BLsif6hSzeniEbkw9mhC4Db2jUYPQOm8G8CKv-ycsrUM-sdPCttDMiISw8QFkRzRnhPwLloOuSpuooKZJbOSFvS6MlDKZS5cPonHm7cWT31A=', start_index=12636)
Annotation(end_index=12649, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzDTVXrXgSBCCjwzxsBEP-MDf8xcF5GhPgJmXckPK_yGQjfHhIRuXTktzapXE6a9LoTs0KFJs3KDIIcjw5eGoRzxKJcItxd_70Ad8Ex0uCYyj1j34QfAemogNPdUcs4OY_ME2AVYoz6hVqMSuw6Q7e7tCZ_onWcC5mr1It08_JOnjXI-6qmffl1fTdcKFX48qckF_85YQBYDd6Bw53gf2jbihuh87pAoDcFrJjfQ7w8t9ejWVcFzRcFI9xNTsXSwScZ0Y1wA==', start_index=12636)
Annotation(end_index=13147, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFl9EDBoadPPswC29Fp7bXtTj2chlUX-18XZgXhTyPk5lDdrRmWT4Ou65duH2KtAExMznpX-VuGnRbPnjRA2CuUfDQlWTq0efG9k2Q4v2FIQQPKdL2YhCyT81FI4zZY01He2g1YIEa0tyu4-H7S6Gb', start_index=13134)
Annotation(end_index=13147, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHtoNRiF95wCg8st5Hfv49NI1oCYeOkSCTnivZwx6CnRlXM6ED5EXirZDWQtc6LYBujG0nhtEqA9qzdaItkmT_AuwpPcAee1rREl-i587dHvqYG6fmQ_-kpFmgrbmBVQWtqS7fi9NBEXFbB6zdFRzczABLjRwiufzkTOgk1uxQZ3bszaMOyvgBdcTWio2EDm5PYxzDSEabglljqi2D_0neO62qps_A=', start_index=13134)
Annotation(end_index=15071, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa8Bv-qGqRsBsoZDSQ83OiQtFw3LHaq_EO39QpuZ7DXGWpUE2QLMykWc18G2FQWQX1jbyAbt0lA2pByLmfKxaxibys8hYUnmvIRMDbFupzzqqd9u7YiZGWIJfTYPs6dkxs36R661tcxQ==', start_index=15058)
Annotation(end_index=15071, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGR4VbYxtue6YbMuKei4mPcnjDTf-saHdXjKoLXYaO8Ee4eQ58WiXqF4AstFBoIZ_4lqBrGWzhdKa4v_xwr1hGTB40OTI6oxl0wzlWj91oxRbVST7iHZVbBBjR9Fp8iifxj3DwKlXx1ZHLuR0-2qSTFr1tzyYU5Z0JX-IOCBijJIbvivhQzAHgeWHKUDchLAobnG1uYQa7LuA5pboYO9nZiZUC0lj1dVTBJn-lGWTzVjqrY1S5qvg2Oh3Y93Y3jUfsQR35ZQqKdIWtEmgJ1nvTm5La-G8fTk7Z8gZtP7WXQxWY80w==', start_index=15058)
Annotation(end_index=15407, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFjQnKkuIGXegkojun8BjLgc55orBZ7Y92HgL1jjnbuF8ZsHdHnZvuHcQ3Cq4DpRlJZQm1CBf1xuuX0fH_7ZOyYRJ8asc521Ci_Jy7wtCRPtSHJZsRHIdAW2g4O8joUDwDs7vmk9DTEepSgotSbkRCs49csrB9KKi-xK2xBlmehjuGFdg0=', start_index=15397)
Annotation(end_index=16180, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFFnrOoBRAP363aXKYOFE3kAlhDkDUTOau-EwzgkMUQFRvBcD3KcFsZxQD0zrCHu2kSjRPt833IDUGNNINM9kWV8NZGmeCqwUehwm6bJs035Uu2Z0Af_j57L8b0S8MC2CftfZgnVUwjvZlE4GYOgtc0UQNx16DMO8I6ep7QR4brA2-mKw_aHGrAu_yZ54vFeWLjXkd8P_uAX-kuubdt6MKkv8GWZm7d_zi5dfyJPXktLhnrbeFXxxX-rL17ADIeXKJFkae2RGqaDbpvKRR6hNFsrwKIQgcJVLYRErUeyJRmu5PUNIZMbltqC8zaV_dEy0ky2R6BOSFgRrbjr67yVGLwHaO88WTlHIYz-sf5d32-_4y0UgiA02sCwRAo2RwxMxNd9R3xGEKlCuMFjS26GIBrh9SHpCoVYWbwwtw2jKEkx2PvtSGzi75FEi03EkOamfKBptP04hJBKZ20MpsCXjqLeJRldvh6E9-faMHNIGU-H5q6UcHd47ZBA==', start_index=16168)
Annotation(end_index=16180, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeyKTYv8vfY4noCGWVtnUmUX8hbf24y6LPUCLcLWzzSIC2ieRzJRjIcPwo1-Z6_qvIvc-PIvYZDoMXeyHBsM1IOmcLlle8lAdWRHOp78xd1HaIzqSq4IdkXMJ9Vw_WQHmpWFrtp8ZiI3mNCYwB0ZIszkImBP82q57CK39y4uIMex8sxgB6i4f2MpbnXc0Y-wwlaOqS6TtFeyUoXeiOF8n1VGf0Gw0yPVeHFBJMmvj0bBpqSM1csZVvPKt_jkhX1otJZINjRwqTKWCrGbH83dBI1e4upumaOMp_q5GSZ1Y=', start_index=16168)
Annotation(end_index=16732, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFW-Pxky1wGb504gRv3mMbXSZEM-81X8Z7B_tovP4sb926fE6-xVlYx5tTVbqtEGdn6mdWOHDhSMB3jF3r1YekUIojxo8OgLVhnqoijZRcg2NwCmBJpxk5OyZFfv1NW9T9qLrlxoRBlFst4eXpE7wkFV5H-auZuZt5u-vHcXsXspuh7QuOl0wfHB8b8G6VHhrlXhk_jvc-ac9kETpvpf_PoKrJXiZCWPhqXoPwbn-i9L4V08cqC4_oVtrJHEaY9GIIycEu6CQ==', start_index=16722)
Annotation(end_index=17550, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8GQNV6EHzQnLT4jfgCEjgfyERwvm_unPbuV_vABJ2MxJ8ZIkKDaG1gFeqWJf37kscef7tXL8mk2vluU9nVq8qUVdV55H-EHRIMPYc-Uz3pTAbFKjOlA==', start_index=17536)
Annotation(end_index=17550, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFrlsik6w8ReVqkoG4M4QZVCKZFVxX1Kvu68mii1B-wuJs95d59bw_RBjTMWds9zGdMUE9EGsjBgoeYG9okhP589bMBHHOz-mFxFBWhAPAtnnLE--16NH3mkvhpuBEjImVpGM3Q9gUMQO4sJ06OlTCCe_UxlrB9UqWsbIYlRREelCwwu_zXA2zcl9S7MwLrbvhutHDRkdKWVq0BV28AQB4wI7Bbyv5W_MlkysvN5oy8NCPwnAGpusTEGXTTrFf7m4hCIqpaaq85NzN2', start_index=17536)
Annotation(end_index=18289, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqXRlzDVoWa30-CzmWFwPNfRLmumKlvd5Y4t8ugONjF0F_37KF8rBkLZc_XeXBHbDwAywQDCK1vIddS_D5UNh5GporhG4VXVDrzLGkdTIRALWLGtuUayjMz8ypqWWP', start_index=18279)
Annotation(end_index=19753, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFFnrOoBRAP363aXKYOFE3kAlhDkDUTOau-EwzgkMUQFRvBcD3KcFsZxQD0zrCHu2kSjRPt833IDUGNNINM9kWV8NZGmeCqwUehwm6bJs035Uu2Z0Af_j57L8b0S8MC2CftfZgnVUwjvZlE4GYOgtc0UQNx16DMO8I6ep7QR4brA2-mKw_aHGrAu_yZ54vFeWLjXkd8P_uAX-kuubdt6MKkv8GWZm7d_zi5dfyJPXktLhnrbeFXxxX-rL17ADIeXKJFkae2RGqaDbpvKRR6hNFsrwKIQgcJVLYRErUeyJRmu5PUNIZMbltqC8zaV_dEy0ky2R6BOSFgRrbjr67yVGLwHaO88WTlHIYz-sf5d32-_4y0UgiA02sCwRAo2RwxMxNd9R3xGEKlCuMFjS26GIBrh9SHpCoVYWbwwtw2jKEkx2PvtSGzi75FEi03EkOamfKBptP04hJBKZ20MpsCXjqLeJRldvh6E9-faMHNIGU-H5q6UcHd47ZBA==', start_index=19741)
Annotation(end_index=19753, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeyKTYv8vfY4noCGWVtnUmUX8hbf24y6LPUCLcLWzzSIC2ieRzJRjIcPwo1-Z6_qvIvc-PIvYZDoMXeyHBsM1IOmcLlle8lAdWRHOp78xd1HaIzqSq4IdkXMJ9Vw_WQHmpWFrtp8ZiI3mNCYwB0ZIszkImBP82q57CK39y4uIMex8sxgB6i4f2MpbnXc0Y-wwlaOqS6TtFeyUoXeiOF8n1VGf0Gw0yPVeHFBJMmvj0bBpqSM1csZVvPKt_jkhX1otJZINjRwqTKWCrGbH83dBI1e4upumaOMp_q5GSZ1Y=', start_index=19741)
Annotation(end_index=19848, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8GQNV6EHzQnLT4jfgCEjgfyERwvm_unPbuV_vABJ2MxJ8ZIkKDaG1gFeqWJf37kscef7tXL8mk2vluU9nVq8qUVdV55H-EHRIMPYc-Uz3pTAbFKjOlA==', start_index=19834)
Annotation(end_index=19848, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFrlsik6w8ReVqkoG4M4QZVCKZFVxX1Kvu68mii1B-wuJs95d59bw_RBjTMWds9zGdMUE9EGsjBgoeYG9okhP589bMBHHOz-mFxFBWhAPAtnnLE--16NH3mkvhpuBEjImVpGM3Q9gUMQO4sJ06OlTCCe_UxlrB9UqWsbIYlRREelCwwu_zXA2zcl9S7MwLrbvhutHDRkdKWVq0BV28AQB4wI7Bbyv5W_MlkysvN5oy8NCPwnAGpusTEGXTTrFf7m4hCIqpaaq85NzN2', start_index=19834)
Annotation(end_index=19966, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa8Bv-qGqRsBsoZDSQ83OiQtFw3LHaq_EO39QpuZ7DXGWpUE2QLMykWc18G2FQWQX1jbyAbt0lA2pByLmfKxaxibys8hYUnmvIRMDbFupzzqqd9u7YiZGWIJfTYPs6dkxs36R661tcxQ==', start_index=19953)
Annotation(end_index=19966, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGR4VbYxtue6YbMuKei4mPcnjDTf-saHdXjKoLXYaO8Ee4eQ58WiXqF4AstFBoIZ_4lqBrGWzhdKa4v_xwr1hGTB40OTI6oxl0wzlWj91oxRbVST7iHZVbBBjR9Fp8iifxj3DwKlXx1ZHLuR0-2qSTFr1tzyYU5Z0JX-IOCBijJIbvivhQzAHgeWHKUDchLAobnG1uYQa7LuA5pboYO9nZiZUC0lj1dVTBJn-lGWTzVjqrY1S5qvg2Oh3Y93Y3jUfsQR35ZQqKdIWtEmgJ1nvTm5La-G8fTk7Z8gZtP7WXQxWY80w==', start_index=19953)
Annotation(end_index=20064, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-oZHp4pPMsmernyW03DSszhLsfL5XmTsRc_uUrA_KWnltmAiIBA7BLsif6hSzeniEbkw9mhC4Db2jUYPQOm8G8CKv-ycsrUM-sdPCttDMiISw8QFkRzRnhPwLloOuSpuooKZJbOSFvS6MlDKZS5cPonHm7cWT31A=', start_index=20055)
Annotation(end_index=20143, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBYATaLTn7sBYi8NpTG6OD9Aznq1oXhG72fuiMMgVMeMBgRVkrhV-eFeJPpo57ERpu71p8kjLrMqPd8VHtaR2fHMb6KUaU6vgy2kDbtt42ZknQyWWTQ0D1NgID086NMPaV_j-KQy_dRqLpKj8vWA==', start_index=20134)
Annotation(end_index=20221, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqXRlzDVoWa30-CzmWFwPNfRLmumKlvd5Y4t8ugONjF0F_37KF8rBkLZc_XeXBHbDwAywQDCK1vIddS_D5UNh5GporhG4VXVDrzLGkdTIRALWLGtuUayjMz8ypqWWP', start_index=20211)
Annotation(end_index=20325, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFjQnKkuIGXegkojun8BjLgc55orBZ7Y92HgL1jjnbuF8ZsHdHnZvuHcQ3Cq4DpRlJZQm1CBf1xuuX0fH_7ZOyYRJ8asc521Ci_Jy7wtCRPtSHJZsRHIdAW2g4O8joUDwDs7vmk9DTEepSgotSbkRCs49csrB9KKi-xK2xBlmehjuGFdg0=', start_index=20315)
Annotation(end_index=20410, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFca7ATJGqD5GtawXGbrzcZcJoLBqFPQjXFoPyhMLuPrBBrwgNeT807zryeG-j1TN62j8NQGLc3e47xZWXP2ZFDWetBErNVZ7EqWEi8Pu1rq3yCvvOHgBT3cPuX5yVsiox_krzNxyDa', start_index=20401)
Annotation(end_index=20503, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFW-Pxky1wGb504gRv3mMbXSZEM-81X8Z7B_tovP4sb926fE6-xVlYx5tTVbqtEGdn6mdWOHDhSMB3jF3r1YekUIojxo8OgLVhnqoijZRcg2NwCmBJpxk5OyZFfv1NW9T9qLrlxoRBlFst4eXpE7wkFV5H-auZuZt5u-vHcXsXspuh7QuOl0wfHB8b8G6VHhrlXhk_jvc-ac9kETpvpf_PoKrJXiZCWPhqXoPwbn-i9L4V08cqC4_oVtrJHEaY9GIIycEu6CQ==', start_index=20493)
Annotation(end_index=20592, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFv-JxPtj3v-QwmMn-j87mhIfFljjWqbiGJKiHlEMk5zw2NOukyKHT28zt6UwDWDY3ZGf0MQPVW-T0Po25qiayNsDn70n1uBecPxO0HJTN6CzqoNTDNqzjenYigC_9zQK59FsqK64zNiNRuCxSJm7lG', start_index=20583)
Annotation(end_index=20713, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFl9EDBoadPPswC29Fp7bXtTj2chlUX-18XZgXhTyPk5lDdrRmWT4Ou65duH2KtAExMznpX-VuGnRbPnjRA2CuUfDQlWTq0efG9k2Q4v2FIQQPKdL2YhCyT81FI4zZY01He2g1YIEa0tyu4-H7S6Gb', start_index=20704)
Annotation(end_index=20808, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-oZHp4pPMsmernyW03DSszhLsfL5XmTsRc_uUrA_KWnltmAiIBA7BLsif6hSzeniEbkw9mhC4Db2jUYPQOm8G8CKv-ycsrUM-sdPCttDMiISw8QFkRzRnhPwLloOuSpuooKZJbOSFvS6MlDKZS5cPonHm7cWT31A=', start_index=20796)
Annotation(end_index=20808, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFh53XqERnWZqPkRiThDwR9sYy5K_9fh2RzSILLBgnbI7weUcHnj9kaCtB6Q_nkftZO5ZmmZ5krC02RLLyuf4LCRnkhZ7Ey7z_Q4oc-jHRTY_AJNzAzLC7LWJK4krIbdQCADSGAcPWGdYOiSObem2hiV3YeJxrdmJDhlmT7EZt5OWivX6g=', start_index=20796)
Annotation(end_index=20903, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9RLXHOAkZXR0w_-FOkWM23Qfk-F7cJrGSH5GteasKpFHorTHy4Ns0sBfg6K--rIs33xXvEKao-OHnPbvAxcGPlal7FK0R6rwUCWULLaXdu1EjWoMi-YFaRA2l5AlqoEo62gAHp_AcL0zaJFa0iXHw1NvdZni3oH68wsVDazfFui6O_VNK7mes8GyUq4nz8ajV4BRHM-QAcs2DQLdGNRuQer3mHUnkSgwyfdS4LgtPPfevy-xzdp_q7_aznRtnK632DPhRp7TlHymwItyiescICtJ8S7BYtM95QltFTZcMJJZoXv1Q9T9WxmIoTQnMn1xRQ5QkRXZG', start_index=20893)
Annotation(end_index=21000, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzDTVXrXgSBCCjwzxsBEP-MDf8xcF5GhPgJmXckPK_yGQjfHhIRuXTktzapXE6a9LoTs0KFJs3KDIIcjw5eGoRzxKJcItxd_70Ad8Ex0uCYyj1j34QfAemogNPdUcs4OY_ME2AVYoz6hVqMSuw6Q7e7tCZ_onWcC5mr1It08_JOnjXI-6qmffl1fTdcKFX48qckF_85YQBYDd6Bw53gf2jbihuh87pAoDcFrJjfQ7w8t9ejWVcFzRcFI9xNTsXSwScZ0Y1wA==', start_index=20990)
Annotation(end_index=23636, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-oZHp4pPMsmernyW03DSszhLsfL5XmTsRc_uUrA_KWnltmAiIBA7BLsif6hSzeniEbkw9mhC4Db2jUYPQOm8G8CKv-ycsrUM-sdPCttDMiISw8QFkRzRnhPwLloOuSpuooKZJbOSFvS6MlDKZS5cPonHm7cWT31A=', start_index=23624)
Annotation(end_index=23636, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFv-JxPtj3v-QwmMn-j87mhIfFljjWqbiGJKiHlEMk5zw2NOukyKHT28zt6UwDWDY3ZGf0MQPVW-T0Po25qiayNsDn70n1uBecPxO0HJTN6CzqoNTDNqzjenYigC_9zQK59FsqK64zNiNRuCxSJm7lG', start_index=23624)
Annotation(end_index=26405, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa8Bv-qGqRsBsoZDSQ83OiQtFw3LHaq_EO39QpuZ7DXGWpUE2QLMykWc18G2FQWQX1jbyAbt0lA2pByLmfKxaxibys8hYUnmvIRMDbFupzzqqd9u7YiZGWIJfTYPs6dkxs36R661tcxQ==', start_index=26393)
Annotation(end_index=26405, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFca7ATJGqD5GtawXGbrzcZcJoLBqFPQjXFoPyhMLuPrBBrwgNeT807zryeG-j1TN62j8NQGLc3e47xZWXP2ZFDWetBErNVZ7EqWEi8Pu1rq3yCvvOHgBT3cPuX5yVsiox_krzNxyDa', start_index=26393)
Annotation(end_index=27853, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFFnrOoBRAP363aXKYOFE3kAlhDkDUTOau-EwzgkMUQFRvBcD3KcFsZxQD0zrCHu2kSjRPt833IDUGNNINM9kWV8NZGmeCqwUehwm6bJs035Uu2Z0Af_j57L8b0S8MC2CftfZgnVUwjvZlE4GYOgtc0UQNx16DMO8I6ep7QR4brA2-mKw_aHGrAu_yZ54vFeWLjXkd8P_uAX-kuubdt6MKkv8GWZm7d_zi5dfyJPXktLhnrbeFXxxX-rL17ADIeXKJFkae2RGqaDbpvKRR6hNFsrwKIQgcJVLYRErUeyJRmu5PUNIZMbltqC8zaV_dEy0ky2R6BOSFgRrbjr67yVGLwHaO88WTlHIYz-sf5d32-_4y0UgiA02sCwRAo2RwxMxNd9R3xGEKlCuMFjS26GIBrh9SHpCoVYWbwwtw2jKEkx2PvtSGzi75FEi03EkOamfKBptP04hJBKZ20MpsCXjqLeJRldvh6E9-faMHNIGU-H5q6UcHd47ZBA==', start_index=27841)
Annotation(end_index=27853, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeyKTYv8vfY4noCGWVtnUmUX8hbf24y6LPUCLcLWzzSIC2ieRzJRjIcPwo1-Z6_qvIvc-PIvYZDoMXeyHBsM1IOmcLlle8lAdWRHOp78xd1HaIzqSq4IdkXMJ9Vw_WQHmpWFrtp8ZiI3mNCYwB0ZIszkImBP82q57CK39y4uIMex8sxgB6i4f2MpbnXc0Y-wwlaOqS6TtFeyUoXeiOF8n1VGf0Gw0yPVeHFBJMmvj0bBpqSM1csZVvPKt_jkhX1otJZINjRwqTKWCrGbH83dBI1e4upumaOMp_q5GSZ1Y=', start_index=27841)
Annotation(end_index=28593, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFl9EDBoadPPswC29Fp7bXtTj2chlUX-18XZgXhTyPk5lDdrRmWT4Ou65duH2KtAExMznpX-VuGnRbPnjRA2CuUfDQlWTq0efG9k2Q4v2FIQQPKdL2YhCyT81FI4zZY01He2g1YIEa0tyu4-H7S6Gb', start_index=28580)
Annotation(end_index=28593, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFW-Pxky1wGb504gRv3mMbXSZEM-81X8Z7B_tovP4sb926fE6-xVlYx5tTVbqtEGdn6mdWOHDhSMB3jF3r1YekUIojxo8OgLVhnqoijZRcg2NwCmBJpxk5OyZFfv1NW9T9qLrlxoRBlFst4eXpE7wkFV5H-auZuZt5u-vHcXsXspuh7QuOl0wfHB8b8G6VHhrlXhk_jvc-ac9kETpvpf_PoKrJXiZCWPhqXoPwbn-i9L4V08cqC4_oVtrJHEaY9GIIycEu6CQ==', start_index=28580)
Annotation(end_index=30104, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzDTVXrXgSBCCjwzxsBEP-MDf8xcF5GhPgJmXckPK_yGQjfHhIRuXTktzapXE6a9LoTs0KFJs3KDIIcjw5eGoRzxKJcItxd_70Ad8Ex0uCYyj1j34QfAemogNPdUcs4OY_ME2AVYoz6hVqMSuw6Q7e7tCZ_onWcC5mr1It08_JOnjXI-6qmffl1fTdcKFX48qckF_85YQBYDd6Bw53gf2jbihuh87pAoDcFrJjfQ7w8t9ejWVcFzRcFI9xNTsXSwScZ0Y1wA==', start_index=30090)
Annotation(end_index=30104, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHlhNEmFC6B4qw2yLSWILFZagATy5TGszpSjqBwdM0sbwljmDgGWZAn9kbmplBaSgm0mUzE-Ox-eY4M4d-u4zQ9VsiWFpGqFZWYIYQvSQvXmMcIn8h89H1OA03EV6P1m-U94oo4lagYtiODFRfWI2Hfc03SozHJ-yF7zJvDH_z5WhxjsUic4l8uIJEZ8_mP6AeGnu23iX9FYxKpQJKnjHw6vuY3N23N5A==', start_index=30090)
Annotation(end_index=31839, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHFFnrOoBRAP363aXKYOFE3kAlhDkDUTOau-EwzgkMUQFRvBcD3KcFsZxQD0zrCHu2kSjRPt833IDUGNNINM9kWV8NZGmeCqwUehwm6bJs035Uu2Z0Af_j57L8b0S8MC2CftfZgnVUwjvZlE4GYOgtc0UQNx16DMO8I6ep7QR4brA2-mKw_aHGrAu_yZ54vFeWLjXkd8P_uAX-kuubdt6MKkv8GWZm7d_zi5dfyJPXktLhnrbeFXxxX-rL17ADIeXKJFkae2RGqaDbpvKRR6hNFsrwKIQgcJVLYRErUeyJRmu5PUNIZMbltqC8zaV_dEy0ky2R6BOSFgRrbjr67yVGLwHaO88WTlHIYz-sf5d32-_4y0UgiA02sCwRAo2RwxMxNd9R3xGEKlCuMFjS26GIBrh9SHpCoVYWbwwtw2jKEkx2PvtSGzi75FEi03EkOamfKBptP04hJBKZ20MpsCXjqLeJRldvh6E9-faMHNIGU-H5q6UcHd47ZBA==', start_index=31827)
Annotation(end_index=31839, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHeyKTYv8vfY4noCGWVtnUmUX8hbf24y6LPUCLcLWzzSIC2ieRzJRjIcPwo1-Z6_qvIvc-PIvYZDoMXeyHBsM1IOmcLlle8lAdWRHOp78xd1HaIzqSq4IdkXMJ9Vw_WQHmpWFrtp8ZiI3mNCYwB0ZIszkImBP82q57CK39y4uIMex8sxgB6i4f2MpbnXc0Y-wwlaOqS6TtFeyUoXeiOF8n1VGf0Gw0yPVeHFBJMmvj0bBpqSM1csZVvPKt_jkhX1otJZINjRwqTKWCrGbH83dBI1e4upumaOMp_q5GSZ1Y=', start_index=31827)
Annotation(end_index=32021, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8GQNV6EHzQnLT4jfgCEjgfyERwvm_unPbuV_vABJ2MxJ8ZIkKDaG1gFeqWJf37kscef7tXL8mk2vluU9nVq8qUVdV55H-EHRIMPYc-Uz3pTAbFKjOlA==', start_index=32007)
Annotation(end_index=32021, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFrlsik6w8ReVqkoG4M4QZVCKZFVxX1Kvu68mii1B-wuJs95d59bw_RBjTMWds9zGdMUE9EGsjBgoeYG9okhP589bMBHHOz-mFxFBWhAPAtnnLE--16NH3mkvhpuBEjImVpGM3Q9gUMQO4sJ06OlTCCe_UxlrB9UqWsbIYlRREelCwwu_zXA2zcl9S7MwLrbvhutHDRkdKWVq0BV28AQB4wI7Bbyv5W_MlkysvN5oy8NCPwnAGpusTEGXTTrFf7m4hCIqpaaq85NzN2', start_index=32007)
Annotation(end_index=32219, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa8Bv-qGqRsBsoZDSQ83OiQtFw3LHaq_EO39QpuZ7DXGWpUE2QLMykWc18G2FQWQX1jbyAbt0lA2pByLmfKxaxibys8hYUnmvIRMDbFupzzqqd9u7YiZGWIJfTYPs6dkxs36R661tcxQ==', start_index=32206)
Annotation(end_index=32219, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGR4VbYxtue6YbMuKei4mPcnjDTf-saHdXjKoLXYaO8Ee4eQ58WiXqF4AstFBoIZ_4lqBrGWzhdKa4v_xwr1hGTB40OTI6oxl0wzlWj91oxRbVST7iHZVbBBjR9Fp8iifxj3DwKlXx1ZHLuR0-2qSTFr1tzyYU5Z0JX-IOCBijJIbvivhQzAHgeWHKUDchLAobnG1uYQa7LuA5pboYO9nZiZUC0lj1dVTBJn-lGWTzVjqrY1S5qvg2Oh3Y93Y3jUfsQR35ZQqKdIWtEmgJ1nvTm5La-G8fTk7Z8gZtP7WXQxWY80w==', start_index=32206)
Annotation(end_index=32366, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF-oZHp4pPMsmernyW03DSszhLsfL5XmTsRc_uUrA_KWnltmAiIBA7BLsif6hSzeniEbkw9mhC4Db2jUYPQOm8G8CKv-ycsrUM-sdPCttDMiISw8QFkRzRnhPwLloOuSpuooKZJbOSFvS6MlDKZS5cPonHm7cWT31A=', start_index=32354)
Annotation(end_index=32366, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFh53XqERnWZqPkRiThDwR9sYy5K_9fh2RzSILLBgnbI7weUcHnj9kaCtB6Q_nkftZO5ZmmZ5krC02RLLyuf4LCRnkhZ7Ey7z_Q4oc-jHRTY_AJNzAzLC7LWJK4krIbdQCADSGAcPWGdYOiSObem2hiV3YeJxrdmJDhlmT7EZt5OWivX6g=', start_index=32354)
Annotation(end_index=32574, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBYATaLTn7sBYi8NpTG6OD9Aznq1oXhG72fuiMMgVMeMBgRVkrhV-eFeJPpo57ERpu71p8kjLrMqPd8VHtaR2fHMb6KUaU6vgy2kDbtt42ZknQyWWTQ0D1NgID086NMPaV_j-KQy_dRqLpKj8vWA==', start_index=32565)
Annotation(end_index=32662, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFqXRlzDVoWa30-CzmWFwPNfRLmumKlvd5Y4t8ugONjF0F_37KF8rBkLZc_XeXBHbDwAywQDCK1vIddS_D5UNh5GporhG4VXVDrzLGkdTIRALWLGtuUayjMz8ypqWWP', start_index=32652)
Annotation(end_index=32787, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFjQnKkuIGXegkojun8BjLgc55orBZ7Y92HgL1jjnbuF8ZsHdHnZvuHcQ3Cq4DpRlJZQm1CBf1xuuX0fH_7ZOyYRJ8asc521Ci_Jy7wtCRPtSHJZsRHIdAW2g4O8joUDwDs7vmk9DTEepSgotSbkRCs49csrB9KKi-xK2xBlmehjuGFdg0=', start_index=32777)
Annotation(end_index=32885, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFca7ATJGqD5GtawXGbrzcZcJoLBqFPQjXFoPyhMLuPrBBrwgNeT807zryeG-j1TN62j8NQGLc3e47xZWXP2ZFDWetBErNVZ7EqWEi8Pu1rq3yCvvOHgBT3cPuX5yVsiox_krzNxyDa', start_index=32876)
Annotation(end_index=33013, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFW-Pxky1wGb504gRv3mMbXSZEM-81X8Z7B_tovP4sb926fE6-xVlYx5tTVbqtEGdn6mdWOHDhSMB3jF3r1YekUIojxo8OgLVhnqoijZRcg2NwCmBJpxk5OyZFfv1NW9T9qLrlxoRBlFst4eXpE7wkFV5H-auZuZt5u-vHcXsXspuh7QuOl0wfHB8b8G6VHhrlXhk_jvc-ac9kETpvpf_PoKrJXiZCWPhqXoPwbn-i9L4V08cqC4_oVtrJHEaY9GIIycEu6CQ==', start_index=33003)
Annotation(end_index=33135, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFv-JxPtj3v-QwmMn-j87mhIfFljjWqbiGJKiHlEMk5zw2NOukyKHT28zt6UwDWDY3ZGf0MQPVW-T0Po25qiayNsDn70n1uBecPxO0HJTN6CzqoNTDNqzjenYigC_9zQK59FsqK64zNiNRuCxSJm7lG', start_index=33126)
Annotation(end_index=33305, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFl9EDBoadPPswC29Fp7bXtTj2chlUX-18XZgXhTyPk5lDdrRmWT4Ou65duH2KtAExMznpX-VuGnRbPnjRA2CuUfDQlWTq0efG9k2Q4v2FIQQPKdL2YhCyT81FI4zZY01He2g1YIEa0tyu4-H7S6Gb', start_index=33296)
Annotation(end_index=33414, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG9RLXHOAkZXR0w_-FOkWM23Qfk-F7cJrGSH5GteasKpFHorTHy4Ns0sBfg6K--rIs33xXvEKao-OHnPbvAxcGPlal7FK0R6rwUCWULLaXdu1EjWoMi-YFaRA2l5AlqoEo62gAHp_AcL0zaJFa0iXHw1NvdZni3oH68wsVDazfFui6O_VNK7mes8GyUq4nz8ajV4BRHM-QAcs2DQLdGNRuQer3mHUnkSgwyfdS4LgtPPfevy-xzdp_q7_aznRtnK632DPhRp7TlHymwItyiescICtJ8S7BYtM95QltFTZcMJJZoXv1Q9T9WxmIoTQnMn1xRQ5QkRXZG', start_index=33404)
Annotation(end_index=33576, source='https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzDTVXrXgSBCCjwzxsBEP-MDf8xcF5GhPgJmXckPK_yGQjfHhIRuXTktzapXE6a9LoTs0KFJs3KDIIcjw5eGoRzxKJcItxd_70Ad8Ex0uCYyj1j34QfAemogNPdUcs4OY_ME2AVYoz6hVqMSuw6Q7e7tCZ_onWcC5mr1It08_JOnjXI-6qmffl1fTdcKFX48qckF_85YQBYDd6Bw53gf2jbihuh87pAoDcFrJjfQ7w8t9ejWVcFzRcFI9xNTsXSwScZ0Y1wA==', start_index=33566)

## Sources
